TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06617325: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Sponsor: UCB Biopharma SRL · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 450 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,772,230

Rescue Site Savings

+$2,498,490

Unlock Full NCT06617325 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06617325 Rescue Dossier →